An Umbrella Review of Meta‐Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia
Mahsa Dabir, Maryam Kamrani Mousavi, Shervin Manteghi, Mohammad Amin Mansoori, Fatemeh Karpasand, Fatemeh Zoghi, Mehrdad Payandeh · 2025
Read An Umbrella Review of Meta‐Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia by Mahsa Dabir, Maryam Kamrani Mousavi, Shervin Manteghi, Mohammad Amin Mansoori, Fatemeh Karpasand, Fatemeh Zoghi, Mehrdad Payandeh (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12703128.txt.
Description
Mahsa Dabir and co-authors summed up prior reviews of a platelet-raising drug for a bleeding disorder in 2025. The disorder, immune thrombocytopenia, makes the body attack its own platelets. The drug, eltrombopag, prods the marrow to make more platelets and is often used after steroids.
The umbrella review gathered nine prior meta-analyses from three databases. Across adult and mixed groups, the drug raised platelet response about threefold and cut bleeding. Child results pointed the same way but with wider spread. Side effects included liver-related changes and clot events, so monitoring matters. Gains rose up to a mid dose and then leveled off, which supports tailored dosing.
Catalog record
| CREATOR | Mahsa Dabir, Maryam Kamrani Mousavi, Shervin Manteghi, Mohammad Amin Mansoori, Fatemeh Karpasand, Fatemeh Zoghi, Mehrdad Payandeh |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |